ConductScience.org, home

Drug · CHEMBL754

FOSCARNET SODIUM

7 sourcespipelines-2026-09-18-0.3.1

Download JSON
Cite this record

ConductScience Library. FOSCARNET SODIUM. Drugs and targets, record CHEMBL754. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL754

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name
FOSCARNET SODIUM
ChEMBL
ChEMBL ID
CHEMBL754
ChEMBL
Type
Small molecule
ChEMBL
Brand names
Foscavir
ChEMBL
Other names
A-29622, EHB 776, EHB-776, Foscarnet de sodio, Foscarnet sodique, Foscarnet sodium anhydrous, Foscarnet sodium hexahydrate, Foscarnet sodium hydrate, Foscarnet trisodium hexahydrate, NSC-313410, NSC-758148
ChEMBL
Parent form
FOSCARNET, CHEMBL666
Drugs and targets
InChIKey
DFHAXXVZCFXGOQ-UHFFFAOYSA-K
ChEMBL
Open Targets' highest stage
Approval, for 3 of its 6 diseases, from DailyMed and TTD
Open Targets

Targets0

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

None in this release.

Diseases6

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DiseaseOpen Targets' stageStage reported byReportsOf them trialsIts drugs
cytomegalovirus retinitisApprovalDailyMed and TTD53https://conductscience.org/library/drugs?q=MONDO_0000878
AIDSPhase 2ClinicalTrials.gov22https://conductscience.org/library/drugs?q=MONDO_0012268
HIV infectious diseasePhase 1ClinicalTrials.gov11https://conductscience.org/library/drugs?q=MONDO_0005109
cytomegalovirus infectionUnknownClinicalTrials.gov11https://conductscience.org/library/drugs?q=MONDO_0005132
inborn error of immunityApprovalDailyMed10https://conductscience.org/library/drugs?q=MONDO_0003778
pneumoniaApprovalDailyMed10https://conductscience.org/library/drugs?q=MONDO_0005249

Trials8

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

TrialTitlePhaseParticipantsResults first postedNamed asLinked bySource
NCT00000691
A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure
Phase 2156foscarnet sodiumIts nameClinicalTrials.gov
NCT00002125A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)Phase 4112foscarnet sodiumIts nameClinicalTrials.gov
NCT02151240Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes ZosterPhase 494foscarnet sodiumIts nameClinicalTrials.gov
NCT00002146
Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study
Phase 412foscarnet sodiumIts nameClinicalTrials.gov
NCT00000729A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional DiseasePhase 110foscarnet sodiumIts nameClinicalTrials.gov
NCT00002021An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficienciesfoscarnet sodiumIts nameClinicalTrials.gov
NCT00002039An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patientsfoscarnet sodiumIts nameClinicalTrials.gov
NCT01199562Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant153foscarnet sodiumIts nameClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
9868672RESULT1PubMed
1646585RESULT1PubMed

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
ClinicalTrials.gov
2026-11-05
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
Papers the trials list, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
Tests named in the trials, as ScienceGraph matched them
2026-11-12
ConductCognition

Sources 7

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ConductCognition's list of its testsOur own data
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL754

GET https://conductscience.org/api/drugs/v1/CHEMBL754/targets